Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
48 stopped studies mapped to Malignant Infratentorial Neoplasm and descendants · 94% state a reason
Over the 48 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | — | withdrawn | Jun 22, 2026 | West China Hospital | Study withdrawn prior to enrollment due to administrative review | Enrollment / accrual |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | Phase 2 | terminated | Jun 2, 2017 | National Cancer Institute (NCI) | Support was withdrawn from study resulting in early termination of study. Investigator had to close… | Drug supply |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young… | — | terminated | Jul 7, 2023 | Pediatric Brain Tumor Consortium | The NCI will not extend the PBTC grant beyond March 31, 2026. | Other (stated, no rule matched) |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and… | Phase 1 | withdrawn | Jun 20, 2024 | Jeffrey Treiber | Inability to find participants meeting eligibility critieria | Other (stated, no rule matched) |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma… | Phase 1 / Phase 2 | terminated | Apr 5, 2019 | Pediatric Brain Tumor Consortium | The decision to permanently close PBTC-053 was made following communication from the NCI that the… | Other (stated, no rule matched) |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy…(BRAVO) | Phase 1 | terminated | Jan 11, 2018 | University of Florida | Not feasible to accrue due to competing studies | Enrollment / accrual |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed…(PersoMed-I) | Phase 2 | terminated | May 26, 2020 | European Organisation for Research and Treatment of Cancer - EORTC | Poor accrual | Enrollment / accrual |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | Phase 2 | suspended | Apr 19, 2016 | Burzynski Research Institute | Clinical Hold | Other (stated, no rule matched) |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including… | Phase 1 / Phase 2 | terminated | Nov 6, 2017 | Alaunos Therapeutics | Sponsor decision due to slow accrual | Enrollment / accrual |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive… | Phase 1 | terminated | Mar 18, 2021 | Columbia University | FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022… | Sponsor / business decision |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System… | Phase 1 / Phase 2 | terminated | Oct 1, 2018 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase 1 | terminated | Jan 31, 2018 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in… | Phase 2 | suspended | Nov 17, 2021 | SonALAsense, Inc. | The study is suspended due to lack of funding but not due to safety concerns. | Safety / toxicity |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Giselle Sholler | Lack of enrollment | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | Phase 1 | terminated | Apr 10, 2020 | Dana-Farber Cancer Institute | Withdrawal of support from BMS | Other (stated, no rule matched) |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Y-mAbs Therapeutics | Business priorities | Sponsor / business decision |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse… | Phase 1 | withdrawn | Oct 1, 2021 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial… | Phase 1 / Phase 2 | terminated | Jun 24, 2013 | Weill Medical College of Cornell University | The study was prematurely closed in December 2021 due to low accrual. | Enrollment / accrual |
| NCT02212574 | Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt… | Early Phase 1 | terminated | Aug 8, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Participant relapses led to abrupt stop of study. | Other (stated, no rule matched) |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or… | Phase 1 | terminated | Oct 2, 2014 | Pediatric Brain Tumor Consortium | Data for the primary objectives is complete and the MTD identified in Stratum II. | Other (stated, no rule matched) |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse… | Phase 2 | terminated | May 2, 2016 | Meyer Children's Hospital IRCCS | Study was terminated due to high heterogeneity of enrolled patients | Enrollment / accrual |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Phase 1 / Phase 2 | terminated | Nov 17, 2015 | Children's Hospital Medical Center, Cincinnati | A competing trial was opened for patient population with combination of ribociclib and everolimus. | Other (stated, no rule matched) |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After… | Phase 3 | terminated | Nov 19, 2013 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | Phase 1 | terminated | Jul 22, 2011 | Masonic Cancer Center, University of Minnesota | Treatment ineffective; Extreme toxicity | Safety / toxicity |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive… | Phase 2 | terminated | Feb 17, 2016 | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Lack of additional funding; patients (3) no longer receiving intervention. | Funding |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | Early Phase 1 | withdrawn | Aug 9, 2019 | University of Michigan Rogel Cancer Center | Withdrawn by Principal Investigator | Investigator |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 2 | terminated | Aug 16, 2010 | Karen D. Wright MD | Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or… | Enrollment / accrual |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With… | Phase 2 | withdrawn | Aug 15, 2018 | University of Michigan Rogel Cancer Center | low accrual | Enrollment / accrual |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in… | Phase 1 / Phase 2 | terminated | May 17, 2012 | Centre Leon Berard | The number of successes is not reached at the end of first stage of the phase II. The study is… | Other (stated, no rule matched) |
| NCT00031590 | Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly… | Phase 2 | terminated | Jan 27, 2003 | Children's Hospital of Philadelphia | The study was terminated prematurely due to slow accrual. | Enrollment / accrual |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | N/A | terminated | Nov 4, 2010 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade… | Phase 1 / Phase 2 | terminated | Jan 7, 2015 | University of Louisville | Transition to a different immunotherapy strategy in the future at our institution | Sponsor / business decision |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | Phase 2 | withdrawn | Jan 6, 2017 | Sue O'Dorisio | This project has undergone a significant amount of updates and has been resubmitted under IRB#… | Other (stated, no rule matched) |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young… | N/A | withdrawn | Jul 18, 2014 | Sue O'Dorisio | not stated | Not stated |
| NCT02967380 | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in… | N/A | terminated | Nov 18, 2016 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | Phase 1 | withdrawn | May 24, 2013 | Medical University of South Carolina | Feasibility of the trial was proven to be absent. | Other (stated, no rule matched) |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | Phase 1 | withdrawn | Oct 2, 2012 | Eli Lilly and Company | Trial stopped early for poor accrual. | Enrollment / accrual |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of… | Phase 1 | terminated | May 4, 2005 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials